NCCAM on echinacea
This article was originally published in The Tan Sheet
Executive Summary
The National Center for Complementary & Alternative Medicine has revised its website "to correct erroneous statements [NCCAM] had made previously" about a study on low-dose echinacea, the NIH center announces Oct. 12. The American Herbal Products Association suggested in an Oct. 4 letter to NCCAM Director Stephen Straus that the revisions be made (1"The Tan Sheet" Oct. 10, 2005, In Brief). The revisions include the removal of the sentence "what's on the label may not always be what's in the bottle," as well as a statement made by Straus endorsing the echinacea study critics felt was inconclusive. NCCAM also added a disclaimer statement as well as one clarifying the dosage used in the trial. The study appeared in the July 28 New England Journal of Medicine (2"The Tan Sheet" Aug. 1, 2005, p. 13)...
You may also be interested in...
AHPA on NCCAM
"AHPA requests that a statement about the potential for mislabeling of dietary supplements that contain echinacea, and herbal preparations generally, be removed from the NCCAM website, and that inaccurate statements attributed to you by numerous news media about a recent study on echinacea be corrected," AHPA states in an Oct. 4 communication to NCCAM Director Stephen Straus, MD. The letter addresses Straus' comment: "Preparations of echinacea, like any herb, can be variable - what's on the label may not always be what's in the bottle." The second clause is a "gratuitous criticism of the industry," the trade group says. AHPA also asks NCCAM to clarify recent "erroneous" statements the center made to The New York Times and The Los Angeles Times regarding echinacea dosages. AHPA separately requested that FDA correct statements about supplements in the GMP final rule...
Echinacea Ineffective For Cold Prevention, Treatment – NEJM Study
Neither preemptive nor early treatment with echinacea prevents the common cold or reduces the severity of its symptoms, a study published in the July 28 New England Journal of Medicine states
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.